⌕
Alumis · ALMS · Nasdaq
Tenet 55 · Mixed
Compare
$5.14−8.21%At closeTenet 55 · Mixed
$5.14−0.46 (−8.21%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Alumis (ALMS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 12, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rat…

● Defense WorldNov 6, 2026 · 02:15 ET
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 According to Brokerages

Shares of Alumis Inc. (NASDAQ: ALMS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen research firms that are covering the stock, Marketbeat.com reports. One research analyst…

● Defense WorldOct 12, 2026 · 02:15 ET
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27

Alumis Inc. (NASDAQ: ALMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has ra…

● GlobeNewsWireOct 9, 2026 · 04:00 ETCOMPANY'S OWN WORDS
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib's potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching f…

● Defense WorldOct 6, 2026 · 03:17 ET
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis

Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength …

● Defense WorldSep 16, 2026 · 01:29 ET
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review

Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the s…

● Defense WorldSep 15, 2026 · 03:18 ET
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)

Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength…

● Seeking AlphaSep 14, 2026 · 10:41 ET
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Defense WorldSep 5, 2026 · 03:48 ET
226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp acquired a new stake in Alumis Inc. (NASDAQ: ALMS) during the second quarter, according to its most recent filing with the SEC. The firm acquired 226,618 shares of the company's stock, valued…

● GlobeNewsWireSep 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Alumis to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases,…

● Seeking AlphaSep 1, 2026 · 16:36 ET
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside

Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The recent share price crash…

● Seeking AlphaSep 1, 2026 · 12:24 ET
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript…

● MarketBeatSep 1, 2026 · 11:03 ET
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said …

● ReutersSep 1, 2026 · 09:16 ET
Alumis eyes late-stage lupus study despite trial miss

Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in ​a smaller subset of patients, even after the treatment failed ‌to meet the main goal of a mid-stage trial.…

● GlobeNewsWireSep 1, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving…

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.